The outlook and analysis of BioAtla Inc. (BCAB)’s stock

BioAtla Inc. [BCAB] stock is trading at $9.51, up 8.07%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAB shares have gain 6.49% over the last week, with a monthly amount glided 38.43%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 8, November 2022, BioAtla to Participate in the Jefferies London Healthcare Conference. In a post published today on Yahoo Finance, BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri Lydick, Senior Vice President, Commercial Strategy will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 15-17, 2022.

From an analyst’s perspective:

BioAtla Inc. [NASDAQ: BCAB] stock has seen the most recent analyst activity on September 15, 2022, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $17. Previously, Credit Suisse downgraded its rating to Neutral on May 05, 2022, and dropped its price target to $5. On March 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. ROTH Capital initiated its recommendation with a Buy and recommended $75 as its price target on June 28, 2021.

BioAtla Inc. [BCAB] stock has fluctuated between $2.01 and $26.20 over the past year. Currently, Wall Street analysts expect the stock to reach $27.71 within the next 12 months. BioAtla Inc. [NASDAQ: BCAB] shares were valued at $9.51 at the most recent close of the market. An investor can expect a potential return of 191.38% based on the average BCAB price forecast.

Analyzing the BCAB fundamentals

Gross Margin for this corporation currently stands at -432.00% with Operating Margin at -38576.00%, Pretax Margin comes in at -38160.80%, and Net Margin reading is -38160.80%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.02 points at the first support level, and at 8.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.82, and for the 2nd resistance point, it is at 10.14.

BioAtla Inc. [BCAB] reported earnings per share of -$0.77 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.69/share, meaning a difference of -$0.08 and a surprise factor of -11.60%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.65 per share as compared to estimates of -$0.67 per share, a difference of $0.02 representing a surprise of 3.00%.

Ratios To Look Out For

For context, BioAtla Inc.’s Current Ratio is 7.70. As well, the Quick Ratio is 12.48, while the Cash Ratio is 12.36. Considering the valuation of this stock, the price to sales ratio is 2,713.75, the price to book ratio is 3.47.

Transactions by insiders

Insider trading has also been a hot topic recently, with 2 insiders purchasing 3,000 shares and 12 selling 10,529 shares in the past 3 months. Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Nov 22 when 2000.0 shares were purchased. Director, MCBRINN SYLVIA completed a deal on Sep 13 to buy 1000.0 shares. Meanwhile, Director MCBRINN SYLVIA bought 2000.0 shares on Sep 12.